

Datasheet for 400-001-MT2**Recombinant Anti-CD20 Fab Antibody****Overview**

Description:	Humanized Recombinant Anti-Human CD20 Fab fragment Antibody - 400-001-MT2
Item No.:	400-001-MT2
Size:	50 µg
Applications:	FC
Reactivity:	Human
Expressed in:	HEK293

Product Details

Background:	CD20 is a 33-37 kD, four transmembrane spanning protein, also known as B1 and Bp35. CD20 is expressed on pre-B-cells, resting and activated B cells (not plasma cells), some follicular dendritic cells, and at low levels on a T cell subset. CD20 is heavily phosphorylated on activated B cells and malignant B cells. Homo-oligomeric complexes of CD20 are thought to form Ca ²⁺ conductive ion channels in the plasma membrane of B cells. The CD20 molecule is involved in B-cell activation and is associated with various Src family kinases (Lyn, Lck, Fyn). It exists in a complex with MHC class I and II, CD53, CD81, and CD82. Anti-CD20 antibody, Rituximab, sold under the brand name Rituxan, is a medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in non-geriatric patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. Biosimilars of Rituxan include Blitzima, Riabni, Ritemvia, Rituenza (F.K.A. Tuxella), Rixathon, Ruxience, and Truxima. This antibody is made from a Rituximab Fab fragment making it specific, efficient, and effective. Recombinant Anti-CD20 Fab fragment Antibody is useful for researchers interested in autoimmune disease and cancer research.
Synonyms:	Membrane Spanning 4-Domains A1, Recombinant Monoclonal CD20, RabMab CD20, Bp35, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, MS4A2, CD20, B1, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A1, S7, Rituximab, Rituxan
Expressed in:	HEK293
Clonality:	Recombinant Monoclonal

Clone ID:	Abz522
Format:	IgG Fab

Target Details

Gene Name:	MS4A1
Reactivity:	Human
Immunogen Type:	Recombinant Protein
Purity/Specificity:	Humanized Recombinant CD20 Fab fragment was expressed in HEK293 cells. Purified by one-step purification by HisTrap FF Crude. The purity was estimated to be >95% by SDS-PAGE analysis.
Relevant Links:	• UniProtKB - P11836 • NCBI - NP_068769.2 • GenelD - 931

Application Details

Tested Applications:	FC
Application Note:	Recombinant Anti-CD20 Fab fragment Antibody has been tested for use in Flow Cytometry. This antibody recognizes structured CD20 and will work in western blot when the protein has not been denatured with DTT or bMe. Although not tested, this antibody could be useful in in IHC and in in-vivo and other cellular assays. Specific conditions for reactivity should be optimized by the end user.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	User Optimized
FC:	User Optimized
WB:	User Optimized

Formulation


Physical State:	Liquid (sterile filtered)
Concentration:	0.36 mg/mL by UV absorbance at 280 nm
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Preservative:	None
Stabilizer:	30% Glycerol

Shipping & Handling

Shipping Condition:	Wet Ice
Storage Condition:	Store vial at -20° C. Dilute only prior to immediate use.
Expiration:	Expiration date is six (6) months from date of receipt.

Images



SDS-PAGE

SDS-PAGE of Humanized Recombinant Anti-human CD20 Fab fragment Antibody. Lane M1: Molecular Weight Ladder. Lane 1: recombinant Anti-human CD20 Fab fragment [reduced]. Lane 2: recombinant Anti-human CD20 Fab fragment [non-reduced]. Coomassie stained.

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.